Answers are grounded in this paper and cite their sources.
Demonstrates the inhibition of alpha-synuclein aggregation in an animal model of Parkinson's disease, suggesting a potential therapeutic approach.
Significance Parkinson’s disease is characterized by the accumulation of amyloid deposits in dopaminergic neurons, mainly composed of the protein α-synuclein. The disordered nature of α-synuclein and its complex aggregation reaction complicate the identification of molecules able to prevent or revert the formation of these inclusions and the subsequent neurodegeneration. By exploiting a recently developed high-throughput screening assay, we identified SynuClean-D, a small compound that inhibits α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.
No takes yet. Share an insight, caveat, or question.
Pujols et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: